ELSEVIER

Contents lists available at ScienceDirect

Stem Cell Research

journal homepage: www.elsevier.com/locate/scr



Lab Resource: Stem Cell Line

Generation of the human induced pluripotent stem cell (hiPSC) line PSMi002-A from a patient affected by the Jervell and Lange-Nielsen syndrome and carrier of two compound heterozygous mutations on the KCNQ1 gene



Manuela Mura ^{a,b}, Yee-ki Lee ^{c,d}, Monia Ginevrino ^{e,f}, Rita Zappatore ^g, Federica Pisano ^{a,b,h}, Marina Boni ^g, Federica Dagradi ⁱ, Lia Crotti ^{i,j}, Enza Maria Valente ^{e,f}, Peter J. Schwartz ⁱ, Hung-Fat Tse ^{c,d}, Massimiliano Gnecchi ^{a,b,h,k,*}

- ^a Coronary Care Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
- b Laboratory of Experimental Cardiology for Cell and Molecular Therapy, IRCCS Policlinico San Matteo Foundation, Pavia, Italy
- ^c Cardiology Division, Department of Medicine, The University of Hong Kong, Hong Kong, China
- d Hong Kong-Guangdong Joint Laboratory on Stem Cell and Regenerative Medicine, The University of Hong Kong, Guangzhou Institutes of Biomedicine and Health, Hong Kong, China
- ^e Department of Molecular Medicine, University of Pavia, Pavia, Italy
- ^f Neurogenetics Unit, IRCCS Santa Lucia Foundation, Rome, Italy
- g Laboratory of Oncohaematological Cytogenetic and Molecular Diagnostics, Division of Haematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- ^h Department of Molecular Medicine, Unit of Cardiology, University of Pavia, Pavia, Italy
- ¹ IRCCS Auxologic Italian Institute, Center for Cardiac Arrhythmias of Genetic Origin, Laboratory of Cardiovascular Genetics, Milan, Italy
- ^j Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital IRCCS Auxologic Italian Institute, Milan, Italy
- ^k Department of Medicine, University of Cape Town, Cape Town, South Africa

ARTICLE INFO

Article history: Received 16 February 2018 Received in revised form 9 March 2018 Accepted 4 April 2018 Available online 07 April 2018

ABSTRACT

We report the generation of human induced pluripotent stem cells (hiPSCs) from dermal fibroblasts of a female patient carrier of the two compound heterozygous mutations c.568 C>T p.R190W (maternal allele), and c.1781 G>A p.R594Q (paternal allele) on the KCNQ1 gene, causing Jervell and Lange-Nielsen Syndrome (JLNS). To obtain hiPSCs, we used the classical approach of the four retroviruses each encoding for a reprogramming factor OCT4, SOX2, KLF4, cMYC. The obtained hiPSC clones display pluripotent stem cell characteristics, and differentiate into spontaneously beating cardiomyocytes (hiPSC-CMs).

© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Resource table.

Unique stem cell line PSMi002-A identifier Alternative name of HDF30-JLNS-iPS stem cell line Fondazione IRCCS Policlinico San Matteo Institution Contact information of Massimiliano Gnecchi, m.gnecchi@unipv.it distributor Type of cell line hiPSC Origin Human Additional origin info Age: 10 Gender: female

Ethnicity: Caucasian
Cell source Dermal fibroblasts
Clonality Clonal

Method of Retroviruses encoding for the human cDNA of OCT4,

reprogramming SOX2, cMYC, KLF4

Genetic modification No Type of modification N/A

Associated disease Jervell and Lange-Nielsen Syndrome (OMIM #220400)

568 C>T and 1781 A>G mutations on KCNQ1

(NM_000218.2)

Method of N/A modification
Name of transgene or resistance
Inducible/constitutive N/A system

Date archived/stock Jan 7, 2013

date

Gene/locus

(continued on next page)

^{*} Corresponding author at: Fondazione IRCCS Policlinico San Matteo, Unità Coronarica, DEA Torre A, Viale Golgi 19, 27100 Pavia, Italy.

E-mail address: m.gnecchi@unipv.it. (M. Gnecchi).

Cell line repository/bank Ethical approval No

The study has been approved by the Ethics Committee of our Institution, Fondazione IRCCS Policlinico San Matteo, on the 29th of October 2010, protocol number 20100004354, proceeding P-20100003369. We obtained patient written informed consent for both skin biopsy procedure and conservation of biological samples.

Resource utility

It has been proven that iPSCs and iPSC-CMs can be efficiently used to model LQTS, and test targeted therapies (Gnecchi et al., 2017; Mehta et al., 2017; Mura et al., 2017; Rocchetti et al., 2017). The PSMi002-A cell line can be used for: 1) modelling of JLNS; 2) targeted drug testing.

Resource details

The PSMi002-A line was generated by reprogramming of dermal fibroblasts isolated from skin biopsy of a 10 years old girl affected by Jervell and Lange-Nielsen Syndrome (JLNS). JLNS is a recessive form of Long QT Syndrome associated with bilateral hearing loss, marked prolongation of the QT interval at the surface ECG, and a propensity for life-threatening cardiac arrhythmias and sudden cardiac death (Jervell and Lange-Nielsen, 1957). The enrolled patient has a severe, bilateral sensorineural hearing loss, a significantly prolonged QTc (QT corrected for heart rate of 578 ms), and experienced several syncopal episodes since age 2. At 7 years the diagnosis of JLNS was performed, beta-blocker therapy was started and no other cardiac events occurred. The patient carries two compound heterozygous mutations on the KCNQ1 gene: the c.568 C/T on the maternal allele leads to the substitution of the arginine in position 190 with tryptophan; the c.1781 G/A on the paternal allele leads to the substitution of the arginine in position 594 with a

Fibroblasts were reprogrammed by retroviral infection of OCT4, SOX2, KLF4 and c-MYC. The obtained hiPSCs were maintained on feeders, retaining ES-like morphology and pluripotent features up to passage 50. Both fibroblasts and hiPSCs present the disease causing mutations on the KCNQ1 gene, as proved by DNA sequencing (Fig. 1A. The KCNQ1 coding sequence -CDS- used as a reference is the NCBI sequence NM_000218.2) and an identical DNA profile at seven polymorphic loci, as shown by Short tandem Repeat (STR) analysis (submitted in archive with journal). Moreover, the DNA karyotyping revealed normal female karyotype (46, XX) (Fig. 1B). The PSMi002-A uniformly expresses the human ES surface antigens Tumor Related Antigen-1-60 and -1-81 (TRA-1-60 and TRA-1-81), Stage Specific Embryonic Antigen-3 and -4 (SSEA-3, SSEA-4), and shows alkaline phosphatase (AP) activity (Fig. 1C). Likewise, it expresses the pluripotent markers NANOG, OCT4, SOX2 (Fig. 1C and D), REX1, GDF3, ESG1, DPPA2, DPPA4 and NODAL (Fig. 1D), and shows OCT4 promoter demethylation (Fig. 1E, open circles indicate unmethylated CpG dinucleotides, while closed circles indicate methylated CpGs). RT-PCR analysis in Fig. 1F shows no expression of the four viral transgenes (Tg) in naïve fibroblasts (HDF), clear expression of Tg OCT4, SOX2, KLF4 and cMYC in fibroblasts five days after transduction (OSKM) and silencing of the four Tg in the PSMi002-A.

As expected, PSMi002-A spontaneously forms embryoid bodies (EBs) able to differentiate into cells belonging to the three germ layers: endoderm, mesoderm and ectoderm (Fig. 1G). Most importantly, we have successfully differentiated this JLNS cell line into cardiomyocytes displaying spontaneous beating activity, and expressing the sarcomeric proteins alpha-actinin (α -SA) and troponin T (TnT) (Fig. 1H, the insets show areas of cross-striation). We also verified the absence fo mycoplasma contamination in our PSMi002-A line (Fig. 1I).

Materials and methods

Generation and clonal expansion of hiPSCs

The detailed protocol is provided as Supplemental methods.

Briefly, skin fibroblasts were reprogrammed using four retroviral vectors expressing OCT4, SOX2, KLF4 and cMYC. Clonal selection of fully reprogrammed cells was performed manually under sterile conditions and using an EVOS XL Core Imaging System (ThermoFisher), by picking individual clones morphologically similar to embryonic stem cells. Colonies were cut, harvested with a pipette, individually placed into a separate cell culture well and expanded (Table 1).

Mutation analysis

Genomic DNA was extracted with QIAamp DNA Blood Mini kit (Qiagen). KCNQ1 gene sequence was amplified with the GoTaq G2 DNA polymerase (Promega) (see Table 2 for primer sequences). The resulting amplicons were purified and sequenced (Lightrun service - GATC Biotech AG – Germany).

STR analysis

STR analysis was carried out using PowerPlex® CS7 System (Promega) kit, following the manufacturer's protocol. Fragments were run on a 3130xl capillary sequencer (Applied Biosystems). Genotypes were assigned using GeneMarker software (SoftGenetics).

Karyotyping

hiPSCs were blocked at metaphase by exposition to 10 µg/ml demecolcine solution (Sigma Aldrich) for 3 h. Karyotyping was performed using 300 G-banding chromosome analysis.

Fig. 1. Characterization of the PSMi002-A cell line. A. On top schematic representation of the KCNQ1 gene with introns (horizontal lines) and exons (vertical lines/boxes). In the lower panel, DNA sequencing results showing the presence of the mutations 568 C>T and 1781 G>A in the KCNQ1 gene of patient-derived dermal fibroblasts (HDF) and PSMi002-A cell line (hiPSC) derived from the same HDF. The KCNQ1 coding sequence (CDS) used as a reference is the NCBI sequence NM_000218.2. B. Karyotype analysis of PSMi002-A (300 G-bandings) showing normal female karyotype (46, XX). C. Immunofluorescence staining showing uniform expression of the indicated markers of pluripotency in the PSMi002-A. Nuclei were counterstained with Hoechst 33258 (Hoechst, blue). The AP panel reports an alkaline phosphatase colorimetric staining. D. RT-PCR analysis showing expression of the indicated markers of pluripotency in PSMi002-A (hiPSC), compared with their parental fibroblasts (HDF). E. OCT-4 promoter methylation analysis with bisulfite sequencing in patient's dermal fibroblasts (HDF) and in the derived hiPSCs. Open circles indicate unmethylated CpG dinucleotides, while closed circles indicate methylated CpGs. F. RT-PCR analysis showing no expression of the four viral transgenes (Tg) in naïve fibroblasts (HDF), expression of Tg OCT4, SOX2, KLF4 and cMYC five days after transduction (OSKM) and silencing of the four Tg in PSMi002-A. G. Far left panel: floating embryoid bodies (EBs) formed after 7 days of PSMi002-A culture in suspension. Panels on the right: Immunofluorescence staining for markers of the 3 germ layers in iPSC-derived EBs: neuronal class tubulin beta III (Tuj) and microtubule-associated protein 2 (MAP2) for ectoderm, smooth muscle actin (SMA)) and cardiac troponin I (TnI) for mesoderm, and alpha Fetoprotein (AFP) for endoderm. H. Co-immunofluorescence staining for the cardiac sarcomeric proteins alpha-sarcomeric actinin (α-SA, red) and troponin T (TnT, green) in cardiomyocytes differentiated from the PSMi002-A. Nuclei were

Immunocytochemistry

hiPSCs and their derivatives were grown on glass coverslips, and then fixed for 15 min in 4% paraformaldehyde (Affimetrix USB),

permeabilized with 0.1% Triton X-100 (Sigma Aldrich) for 5 min, and blocked in 1% bovine serum albumin (BSA, Sigma Aldrich) for 1 h at room temperature (RT). Then they were incubated for 1 h at RT with the primary antibody (Table 2) diluted in blocking solution,




Table 1
Characterization and validation of PSMi002-A cell line.

Classification	Test	Result	Data
Morphology	Photography	Normal	Not shown but available upon request
Phenotype	Immunocytochemistry Alkaline phosphatase assay	Positive staining for the pluripotency markers Oct4, Nanog, Sox2, TRA-1-60, TRA-1-81, SSEA-3, SSEA-4 Positive staining for the alkaline phosphatase	Fig. 1 panel C Fig. 1 panel C
Genotype	RT-PCR Karyotype (300 G-banding) and	Expression of the pluripotency markers OCT3/4, SOX2, NANOG, REX1, GDF3, ESG1, DPPA2, DPPA4, NODAL 46XX, Resolution 450–500	Fig. 1 panel D Fig. 1 panel B
Identity	resolution Microsatellite PCR	Not performed	
identity	(mPCR) STR analysis	7 sites tested for iPSC, all sites matched with donor HDF STR profile	Online archive
Mutation analysis	Sequencing	Compound heterozygous for the mutations c. 568 C>T p.R190W and 1781 G>A p.R594Q on the KCNQ1 gene	Fig. 1 panel A
Microbiology and virology	Mycoplasma	Mycoplasma testing by RT-PCR. Negative	Fig. 1 panel I
Differentiation potential	Embryoid body formation	The EBs expressed neuronal class tubulin beta III (Tuj) and microtubule-associated protein (MAP) (ectoderm); smooth muscle actin (SMA) and troponin I (mesoderm); alpha fetoprotein (AFP) (endoderm).	Fig. 1 panel G
	Differentiation into cardiomyocytes	The iPSC-derived cardiomyocytes expressed the cardiac sarcomeric proteins alpha-sarcomeric actinin $(\alpha$ -SA) and troponin T (TnT)	Fig. 1 panel H
Donor screening	HIV $1 + 2$ Hepatitis B, Hepatitis C	Not performed	
Genotype additional info	Blood group genotyping HLA tissue typing	Not performed Not performed	

washed three times, and incubated for 1 h at RT with an appropriate secondary antibody (Table 2). Finally, the cells were stained with 1 μ g/ml of Hoechst 33258 (Sigma Aldrich). Images were acquired using the Carl Zeiss fluorescence microscope Observer.Z1 equipped with the Apotome system and AxioVision 6.0 software (Zeiss GmbH, Gottingen, Germany).

AP colorimetric assay

AP was detected by using the Alkaline Phosphatase Staining kit (00-0009 Stemgent).

RT-PCR

Total RNA was purified using TRIzol (ThermoFisher Scientific). cDNA was synthesized using the Superscript II Reverse Transcriptase (ThermoFisher). RT-PCR was performed with the GoTaq G2 DNA polymerase (Promega) and primers in Table 2.

OCT4 promoter demethylation analysis

Genomic DNA was treated with the EZ DNA methylation kit (Zymo Research, Orange, CA, USA). The promoter region of the human OCT4 gene was amplified using Amplitaq gold 360 (Applied Biosystems). The PCR products were sequenced using Pyrosequencing PSQ96 HS System (Biotage, Uppsala, Sweden). The methylation status of each locus was analyzed using PyroQ-CpG software (Qiagen).

EB formation

hiPSCs were grown for 7 days in non-adherent conditions in a modified iPS medium deprived of bFGF and containing 20% FBS instead of KO-SR. Forming EBs were then transferred to gelatin-coated dishes to allow differentiation in adhesion for additional 7 days. Finally, the cells

were processed for immunostaining of the three germ layers as described above.

Cardiac differentiation

Cardiac differentiation was induced using the PSC Cardiomyocyte Differentiation Kit (ThermoFisher).

Mycoplasma test

For the detection of mycoplasma in cell culture we used the EZ-PCR Mycoplasma Test Kit (Biological Industries).

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi. org/10.1016/j.scr.2018.04.002.

References

Gnecchi, M., Stefanello, M., Mura, M., 2017. Induced pluripotent stem cell technology: toward the future of cardiac arrhythmias. Int. J. Cardiol. 237, 49–52.

Jervell, A., Lange-Nielsen, F., 1957. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am. Heart J. 54, 59–68.

Mehta, A., Ramachandra, C.J.A., Singh, P., Chitre, A., Lua, C.H., Mura, M., Crotti, L., Wong, P., Schwartz, P.J., Gnecchi, M., Shim, W., 2017. Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. Eur. Heart J. https://doi.org/10.1093/eurheartj/ehx394.

Mura, M., Mehta, A., Ramachandra, C.J., Zappatore, R., Pisano, F., Ciuffreda, M.C., Barbaccia, V., Crotti, L., Schwartz, P.J., Shim, W., Gnecchi, M., 2017. The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by Long QT Syndrome type 2. Int. I. Cardiol. 240. 367–371.

Rocchetti, M., Sala, L., Dreizehnter, L., Crotti, L., Sinnecker, D., Mura, M., Pane, L.S., Altomare, C., Torre, E., Mostacciuolo, G., Severi, S., Porta, A., De Ferrari, G.M., George Jr., A.L., Schwartz, P.J., Gnecchi, M., Moretti, A., Zaza, A., 2017. Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. Cardiovasc. Res. 113, 531–541.

Table 2 Reagents details.

	Antibody		Dilution	Company Cat # and RRID	
Pluripotency markers	Rabbit anti Nanog		1:200	Stemgent Cat# 09-0020, RRID: AB_2298294	
	Mouse anti Oct3/4 (C-10)		1:500	SCBT Cat# sc-5279, RRID: AB_628051	
	Mouse anti Sox2		1:500	R&D Systems Cat# MAB2018, RRID: AB_358009	
	Mouse anti TRA-1-60		1:100	Stemgent Cat# 09-0010, RRID: AB_1512170	
	Mouse anti TRA-1-81		1:100	Stemgent Cat# 09-0011, RRID: AB_1512171	
	Rat anti SSEA-3		1:100	Millipore Cat# MAB4303, RRID: AB_177628	
	Mouse anti SSEA-4		1:100	Stemgent Cat# 09-0006, RRID: AB_1512169	
Differentiation markers (EBs)	Mouse anti neuronal class tubulin beta	a III (Tui)	1:500	Covance Cat# MMS-435P, RRID: AB_2313773	
	Anti microtubule-associated protein 2 (MAP2)		1:200	Millipore Cat# MAB3418, RRID: AB_94856	
	Mouse anti smooth muscle actin	, ,	1:1000	Millipore Cat# CBL171, RRID: AB_2223166	
	Mouse anti Troponin I (TnI)		1:200	Millipore Cat# MAB1691, RRID: AB_2256304	
	Mouse anti alpha-fetoprotein		1:500	Millipore Cat# SCR030, RRID: AB_597591	
Cardiac markers	Mouse anti Troponin T ^a		1:250	ThermoFisher Cat# MA5-12960, RRID: AB_1100074	
curdide markers	Mouse anti alpha actinin ^a		1:800	Sigma Aldrich Cat# A7811, RRID: AB_476766	
Secondary antibodies	Alexa-Fluor® 488 Goat anti-rabbit IgG		1:500	ThermoFisher Cat# A11008, RRID: AB_143165	
occordary antibodies	Alexa-Fluor® 488 Goat anti-rat IgM		1:500	ThermoFisher Cat# A21212, RRID:AB_11180047	
	Alexa-Fluor® 488 Goat anti-mouse Ig0		1:500	ThermoFisher Cat# A21212, RRID: AB_11180047 ThermoFisher Cat# A11001, RRID: AB_2534069	
	Alexa-Fluor® 546 Goat anti-mouse Igo		1:500	ThermoFisher Cat# A11001, RRID: AB_2334009 ThermoFisher Cat# A11003, RRID: AB_141370	
	Alexa Tuoto 540 doat anti mouse ige	J	1.500	Thermorisher each M17003, RMD. ND_141370	
Primers		Taurah		Formund (navone mimor (F), 20)	
		Target		Forward/reverse primer (5′–3′)	
Targeted mutation analysis/sequencing		KCNQ1 exon 3		Fw: 5'-gttcaaacaggttgcagggtctga-3'	
				Rev: 5'- ccaggtttccagaccaggaag-3'	
		KCNQ1 exon 15		Fw: 5'-ctacctccccagccctac-3'	
				Rev: 5'-caactcccaagaggggcc-3'	
Pluripotency markers (RT-PCR)		OCT4		Fw: 5'-gtactcctcggtccctttcc-3'	
				Rev: 5'-caaaaaccctggcacaaact-3'	
		SOX2		Fw: 5'-acaccaatcccatccacact-3'	
				Rev: 5'-tttttcgtcgcttggagact-3'	
		NANOG		Fw: 5'-ttccttcctccatggatctg-3'	
				Rev: 5'-tctgctggaggctgaggtat-3'	
		REX1		Fw: 5'-cagatcctaaacagctcgcagaat-3'	
				Rev: 5'-gcgtacgcaaattaaagtccaga-3'	
		GDF3		Fw: 5'-cttatgctacgtaaaggagctggg-3'	
		GDIS		Rev: 5'-gtgccaacccaggtcccggaagtt-3'	
		ESG1		Fw: 5'-atatcccgccgtgggtgaaagttc-3'	
		LJG1		Rev: 5'-actcagccatggactggagcatcc-3'	
		DPPA4		0 00 00 0	
		DPPA4		Fw: 5'-ggagccgcctgcctggaaaattc-3'	
		DDDA2		Rev: 5'-tttttcctgatattctattcccat-3'	
		DPPA2		Fw: 5'-ccgtccccgcaatctccttccatc-3'	
		NODAL		Rev: 5'-atgatgccaacatggctcccggtg-3'	
		NODAL		Fw: 5'-gggcaagaggcaccgtcgacatca-3'	
			Rev:5'-gggactcggtgggggctggtaacgtttc-3'		
House-keeping genes (RT-PCR)		GAPDH		Fw 5'-catgttccaatatgattccaccc-3'	
				Rev. 5'-gggatctcgctcctggaagat-3'	
OCT4 promoter demethylation analysis/	OCT4 promoter		Fw: 5'-gaggttggagtagaaggattgttttggttt-3		
				Rev: 5'-ccccctaacccatcacctccaccacctaa-	
Retroviral transgenes		OCT4 cDNA on pMX	s-hOCT3/4	Fw: 5'-ccccagggccccattttggtacc-3'	
		SOX2 cDNA on pMX	s-hSOX-2	Fw: 5'-ggcaccctggcatggctcttggctc-3'	
		cMYC cDNA on pMX		Fw: 5'-caacaaccgaaaatgcaccagccccag-3'	
		KLF4 cDNA on pMX		Fw: 5'-acgatcgtggccccggaaaaggacc-3'	
		pMX viral vector		Rev: 5'-ccctttttctggagactaaataaa-3'	

^a To perform the co-staining with these two antibodies, we used the Zenon Tricolor Mouse IgG labeling Kit (Molecular Probes).